microbiome

Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Endpoints
IPOs
SPAC
Finch Therapeutics
microbiome
Connect Biopharma
Insil Bio
Transcode Therapeutics
Flag link:
MS study points to the gut microbiome as a potential source of the disease
MS study points to the gut microbiome as a potential source of the disease
Fierce Biotech
MS
multiple sclerosis
microbiome
IL-17
Flag link:
Bold Predictions for Medtech in 2021
Bold Predictions for Medtech in 2021
Medical Devices and Diagnostics Industry
devices
Medtech
COVID-19
remote patient monitoring
telemedicine
home care
digital medicine
artificial intelligence
machine learning
robotic surgery
3D printing
Joe Biden
gene editing
microbiome
CAR-T
Flag link:
Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs
Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs
Xconomy
Federation Bio
microbiome
Flag link:
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
Pharmaforum
Vedanta Biosciences
microbiome
C. difficile
BARDA
Flag link:
Arranta Bio set to boost manufacturing for growing pipeline of microbiome drugs
Arranta Bio set to boost manufacturing for growing pipeline of microbiome drugs
BioPharma Dive
Arranta Bio
microbiome
CDMO
drug manufacturing
Flag link:
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline
Xconomy
microbiome
Finch Therapeutics
Seres Therapeutics
Flag link:
Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win
Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win
Fierce Biotech
Seres Therapeutics
SER-109
C. difficile
microbiome
Flag link:
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
Marketwatch
Seres Therapeutics
microbiome
clinical trials
SER-109
Flag link:
Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work
Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work
Endpoints
Takeda
Enterome
microbiome
R&D
Flag link:
Amid Allergan buyout, AbbVie dumps unwanted Assembly microbiome pact
Amid Allergan buyout, AbbVie dumps unwanted Assembly microbiome pact
Fierce Biotech
Assembly Biosciences
microbiome
Allergan
AbbVie
M&A
Flag link:
In big year for microbiome drugs, a small biotech sets the bar
In big year for microbiome drugs, a small biotech sets the bar
BioPharma Dive
biotech
microbiome
Finch Therapeutics
C. difficile
Flag link:
Ferring’s gut microbiome drug clears phase 3 trial in C. diff
Ferring’s gut microbiome drug clears phase 3 trial in C. diff
Pharmaforum
Ferring Pharmaceuticals
clinical trials
microbiome
C. difficile
RBX2660
Flag link:
Heart Drugs May Influence Gut Microbiome In Obese People, Says New Study
Heart Drugs May Influence Gut Microbiome In Obese People, Says New Study
Forbes
microbiome
obesity
statins
Flag link:
Gilead to lean on Second Genome's microbiome work in $38M research pact
Gilead to lean on Second Genome's microbiome work in $38M research pact
BioPharma Dive
Gilead Sciences
Second Genome
microbiome
R&D
Flag link:
Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic
Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic
Fierce Biotech
microbiome
obesity
Kintai Therapeutics
Flag link:
Gut link to Parkinson's sparks talk of probiotic treatment strategy
Gut link to Parkinson's sparks talk of probiotic treatment strategy
Fierce Biotech
Parkinson's Disease
probiotics
microbiome
Flag link:
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
Xconomy
Novome Biotechnologies
microbiome
hyperoxaluria
Flag link:
Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs
Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs
Endpoints
uBiome
microbiome
M&A
Psomagen
JNJ
Pulmatrix
lung cancer
Flag link:
Treating multiple sclerosis with the help of the gut microbiome
Treating multiple sclerosis with the help of the gut microbiome
Fierce Biotech
Brigham and Women's
microbiome
microRNA
multiple sclerosis
MS
Flag link:

Pages